Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously ...
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...
A medication to treat chronic myeloid leukemia (CML) has shown its potential to become the new frontline therapy for people living with the life-threatening blood cancer. Asciminib, is known by the ...
FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing ...
Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older. Background: The phase of chronic myeloid leukemia (CML) at diagnosis (dx) remains significant prognostic factor for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results